tirzepatide antibodies Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis Tirzepatide and the Brain: A

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

A random-effects model meta-analysis, pooling hazard ratios from previous RCTs, was conducted using R software to inform the predictive model

* Try Sculpt Touch Today

GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction

Novo Nordisk's GLP-1 pill gains FDA nod to reduce risk of cardiovascular events

Prescription Weight Loss, Inc